Newland Pharmaceutical Co., Ltd. (SHE:301277)

China flag China · Delayed Price · Currency is CNY
11.53
0.00 (0.00%)
Apr 29, 2026, 4:00 PM EDT
-2.37%
Market Cap 4.52B
Revenue (ttm) 659.54M
Net Income (ttm) 100.78M
Shares Out 392.08M
EPS (ttm) 0.26
PE Ratio 44.75
Forward PE n/a
Dividend 0.20 (1.73%)
Ex-Dividend Date Apr 30, 2026
Volume 1,943,940
Average Volume 3,290,859
Open 11.46
Previous Close 11.53
Day's Range 11.44 - 11.68
52-Week Range 10.80 - 18.38
Beta 0.45
RSI 41.79
Earnings Date Apr 24, 2026

About Newland Pharmaceutical

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, l... [Read more]

Sector Healthcare
Founded 2005
Employees 981
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301277
Full Company Profile

Financial Performance

In 2025, Newland Pharmaceutical's revenue was 672.38 million, a decrease of -7.44% compared to the previous year's 726.44 million. Earnings were 121.25 million, a decrease of -30.17%.

Financial Statements

News

There is no news available yet.